Background

A 54-year-old schoolteacher from Hyderabad was diagnosed with advanced lung cancer after months of persistent cough and fatigue. Following standard treatments, her disease showed limited response, prompting her oncologist to explore newer therapeutic options.

Clinical Recommendation

Under the care of a senior oncologist at a tertiary cancer hospital in Telangana, IMDELLTRA was identified as a potential option based on evolving clinical data and patient-specific factors. However, the medicine was not commercially marketed in India.

Barriers to Access

For Patient and her family, the challenges included:

MitoGENE Intervention

MitoGENE was engaged to manage the access process. The team conducted a structured assessment and educated the family on how NPP works in India.

Support provided:

Detailed explanation of regulatory requirements and timelines

Documentation support including prescription validation and import permits

Coordination with overseas suppliers experienced in NPP shipments

Continuous updates to both the family and the treating physician

Treatment Initiation

Once approvals were obtained, IMDELLTRA was imported under controlled conditions and delivered to Hyderabad. The hospital team initiated therapy with full confidence in the medicine’s provenance and compliance.

Patient Perspective

According to Patient’s husband, “The process felt overwhelming initially, but MitoGENE handled everything step by step. We never felt lost.”

Key Takeaway

This case underlines the importance of structured guidance and regulatory expertise in ensuring timely access to emerging therapies for Indian lung cancer patients.

Disclaimer

MitoGENE facilitates patient-specific access to medicines under Named Patient Program permitted by CDSCO through Form 12B. The products mentioned are not approved for commercial sale in India. Access is strictly for personal use under physician supervision. Information provided on this website is sourced from publicly available references, and MitoGENE is not responsible for its completeness or accuracy. MitoGENE does not promote or sell any specific product and does not replace advice from qualified healthcare professionals.